MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Arbutus Biopharma Corporation DSO Ratio 2011-2025 | ABUS
Annual DSO Ratio Arbutus Biopharma Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.5 | 10.5 | 36.7 | 69.3 | 73.1 | 112 | 29.7 | 170 | 20.3 | 61.7 | 8.71 | 89 | 30.6 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 170 | 8.71 | 57.1 |
Quarterly DSO Ratio Arbutus Biopharma Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 166 | 9.38 | 92.9 | - | 115 | 103 | 117 | - | 46.9 | 51.8 | 27.4 | - | 14.1 | 4.21 | 8.02 | - | 40.5 | 50.2 | 55.6 | - | 78.6 | 79.1 | 77 | 67.9 | 35.9 | 168 | 177 | 53.5 | 53.5 | 74.9 | 35.6 | 14.5 | 5.32 | 35.3 | 131 | -128 | 32.2 | 80.6 | 96.9 | 7.25 | 22.6 | 26.7 | 28.4 | 39.9 | 39.8 | 95.9 | 20.8 | 14.2 | 3.6 | 3.75 | 25.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 177 | -128 | 52.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
267 | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
20.6 | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
57.9 | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
ChromaDex Corporation
CDXC
|
13.2 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
134 | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.29 | -5.01 % | $ 631 M | Israel |
 |
Benitec Biopharma
BNTC
|
141 | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
177 | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
60.8 | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
56.5 | $ 10.89 | -0.09 % | $ 1.42 B | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
157 | - | -5.68 % | $ 8.28 M | USA |